Search research articles
Contact Us
Filters
Showing results (331-340 of 740) with videos related to
Page
of 74
Sort By:
Leukemia & Lymphoma
|
November 6, 2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)
Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, et al.
Advances in Therapy
|
October 17, 2020
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
Vania Hungria, Deborah M Martínez-Baños, María-Victoria Mateos, et al.
Leukemia Research
|
April 16, 2013
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
Paul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Biomedicines
|
February 25, 2022
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, et al.
Plos One
|
February 7, 2015
Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer
Dimitra T Stefanou, Aristotelis Bamias, Hara Episkopou, et al.
Plos One
|
August 5, 2021
Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
Dimitra T Stefanou, Aristotelis Bamias, Hara Episkopou, et al.
Hemasphere
|
June 5, 2023
Prevalence of MGCS Among Patients With Monoclonal Gammopathies
Foteini Theodorakakou, Despina Fotiou, Maria Gavriatopoulou, et al.
Blood
|
April 21, 2012
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
Efstathios Kastritis, Evangelos Terpos, Maria Roussou, et al.
British Journal of Haematology
|
November 14, 2015
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma
Tina Bagratuni, Evangelos Terpos, Evangelos Eleutherakis-Papaiakovou, et al.
Scientific Reports
|
March 3, 2019
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop
Tina Bagratuni, Aimilia D Sklirou, Efstathios Kastritis, et al.
Page
of 74
Search research articles
Search
Showing results (331-340 of 740) with videos related to
Sort By:
Page
of 74
Leukemia & Lymphoma
|
November 6, 2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)
Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, et al.
Advances in Therapy
|
October 17, 2020
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
Vania Hungria, Deborah M Martínez-Baños, María-Victoria Mateos, et al.
Leukemia Research
|
April 16, 2013
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
Paul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Biomedicines
|
February 25, 2022
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, et al.
Plos One
|
February 7, 2015
Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer
Dimitra T Stefanou, Aristotelis Bamias, Hara Episkopou, et al.
Plos One
|
August 5, 2021
Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
Dimitra T Stefanou, Aristotelis Bamias, Hara Episkopou, et al.
Hemasphere
|
June 5, 2023
Prevalence of MGCS Among Patients With Monoclonal Gammopathies
Foteini Theodorakakou, Despina Fotiou, Maria Gavriatopoulou, et al.
Blood
|
April 21, 2012
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
Efstathios Kastritis, Evangelos Terpos, Maria Roussou, et al.
British Journal of Haematology
|
November 14, 2015
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma
Tina Bagratuni, Evangelos Terpos, Evangelos Eleutherakis-Papaiakovou, et al.
Scientific Reports
|
March 3, 2019
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop
Tina Bagratuni, Aimilia D Sklirou, Efstathios Kastritis, et al.
Page
of 74